Celsion is committed to the development of efficient, effective and targeted therapies for the treatment of cancer. Our method is an elegant approach that delivers high concentrations of widely used anti-cancer agents directly to the tumor site, maximizing efficacy while minimizing the side-effects of systemic treatments, with the goal of improving patient outcomes in underserved cancer indications.The focus of our current clinical development efforts is ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, a frequently-used and proven cancer drug. The ThermoDox program offers a "pipeline within a product", with the potential for groundbreaking advancements in the treatment of multiple tumor indications that represent major market opportunities worldwide. In addition, by pairing our novel technology with a proven, approved drug, we have the opportunity to significantly improve upon existing treatment options without the level of risk inherent in the development of new chemical entities. We have designed the HEAT Study to support approval in multiple markets worldwide, and are seeking global partnerships to maximize the commercial potential of this near-term product opportunity.